Amarin (AMRN) vs Gilead Sciences (GILD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Gilead Sciences (GILD) has outperformed Amarin (AMRN) over the past year, gaining 25.7% versus a loss of 37.6%. Over five years, GILD leads with a +117.1% price change compared with -88.4% for AMRN. Gilead Sciences is the larger company by market cap ($179.71 billion vs $251.5 million), about 714.6 times the size.
On valuation, Amarin trades at a lower forward P/E (12.1x vs 14.7x for Gilead Sciences). Gilead Sciences pays a dividend yielding 2.22%, while Amarin does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRN | GILD |
|---|---|---|
| Share price | $11.91 | $144.93 |
| Market cap | $251.47M | $179.71B |
| 1-day change | -0.96% | -1.31% |
| YTD return | -13.90% | +19.64% |
| 1-year return | -37.62% | +25.75% |
| 5-year return | -88.35% | +117.14% |
| Forward P/E | 12.15 | 14.66 |
| EPS (TTM) | $-1.20 | $-2.65 |
| Dividend yield | 0.00% | 2.22% |
| Annual dividend | $0.00 | $3.22 |
| Revenue (latest FY) | — | $29.44B |
| Revenue growth (YoY) | — | +2.40% |
| Net income (latest FY) | — | $8.51B |
| Gross margin | — | 78.83% |
| Operating margin | — | 34.04% |
| Net margin | — | 28.90% |
| 52-week high | $20.90 | $157.29 |
| 52-week low | $11.83 | $114.02 |
| Distance from 52-week high | -43.04% | -7.86% |
| Analyst consensus | none | buy |
| Avg. price target upside | +5.00% | +9.89% |
| Average volume | 66.16K | 6.01M |
| Shares outstanding | 21.12M | 1.24B |
| Employees | 80 | 17,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Gilead Sciences is about 714.6 times larger than Amarin by market value ($179.71B vs $251.47M).
- GILD has outperformed AMRN by 63.4 percentage points over the past year.
- Gilead Sciences offers a meaningfully higher dividend yield (2.22% vs 0.00%).
About Amarin
AMRN stock →Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
About Gilead Sciences
GILD stock →Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17,000 employees
AMRN vs GILD FAQ
Which is bigger, Amarin or Gilead Sciences?
Gilead Sciences (GILD) is larger, with a market capitalization of $179.71B compared with $251.47M for Amarin (AMRN).
Which stock has performed better over the past year, AMRN or GILD?
GILD returned +25.75% over the past 12 months, compared with -37.62% for AMRN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Amarin or Gilead Sciences?
Gilead Sciences pays a dividend yielding 2.22%, while Amarin does not currently pay a regular dividend.
Are Amarin and Gilead Sciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Amarin and Biotechnology: Biological Products (No Diagnostic Substances) for Gilead Sciences.